Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–19 of 19 results
Advanced filters: Author: D. Petitprez Clear advanced filters
  • The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade (nivolumab) in patients with locally advanced or metastatic high-grade sarcoma.

    • Sandra P. D’Angelo
    • Allison L. Richards
    • William D. Tap
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-11
  • Deconvolution methods infer levels of immune infiltration from bulk expression of tumour samples. Here, authors assess 6 published and 22 community-contributed methods via a DREAM Challenge using in vitro and in silico transcriptional profiles of admixed cancer and healthy immune cells.

    • Brian S. White
    • Aurélien de Reyniès
    • Andrew J. Gentles
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-22
  • Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.

    • Florent Petitprez
    • Aurélien de Reyniès
    • Wolf H. Fridman
    Research
    Nature
    Volume: 577, P: 556-560
  • Few studies have suggested that enteric glial cells (EGCs) promote colorectal cancer growth. Here the authors show that EGC-derived IL-6 promotes the expansion of tumorigenic SPP1+ tumor-associated macrophages, associated with worse disease outcome.

    • Lies van Baarle
    • Veronica De Simone
    • Gianluca Matteoli
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-22
  • Multiomic profiling of several cohorts of patients treated with immune checkpoint blockade highlights the presence and potential role of B cells and tertiary lymphoid structures in promoting therapy response.

    • Beth A. Helmink
    • Sangeetha M. Reddy
    • Jennifer A. Wargo
    Research
    Nature
    Volume: 577, P: 549-555
  • Tertiary lymphoid structures (TLSs) form outside of lymphoid tissues at sites of chronic inflammation, including tumours. This Review describes the evidence demonstrating that TLSs are critical for generating antitumour immune responses and are associated with better prognosis in certain cancer types. It also presents potential strategies aimed at inducing TLS neogenesis to improve clinical responses in poorly immunogenic cancers.

    • Catherine Sautès-Fridman
    • Florent Petitprez
    • Wolf Herman Fridman
    Reviews
    Nature Reviews Cancer
    Volume: 19, P: 307-325
  • This Review discusses the complex and context-dependent role of the complement system in cancer, highlighting the opposing effects of complement activation in both promoting and restraining tumour progression. A novel analysis of publicly available transcriptomic data to provide an overview of the prognostic value of complement gene expression in cancer is also included.

    • Lubka T. Roumenina
    • Marie V. Daugan
    • Wolf Herman Fridman
    Reviews
    Nature Reviews Cancer
    Volume: 19, P: 698-715
  • The schematic representation of the tumor immune environment shows the composition and function of a tertiary lymphoid structures (TLS), who are usually found peritumorally in the stroma and/or in the invasive margin. The chemokine CXCL13, produced by CD8+ T cells, induces chemotaxis by binding to the receptor CXCR5, mainly expressed by B cells and TFH cells, and regulates the organization of B cells inside the follicles of lymphoid tissues. The TLS consists out of a T cell-rich zone containing mature dendritic cells (DCs), in close proximity to GC containing follicle like-B cells, intermingled with follicular dendritic cells (FDCs) and surrounded by plasma cells and helper-innate lymphoid cell group 3 (ILC3) at the edge of the TLS. In the optimally organized TLS immune structure, DCs, FDCs, T cells and B cells interact and activate each other, promoting a local sustained immune response including the induction of T cell effector function, antibody generation, and clonal expansion. The stroma surrounding the tumor epithelium and the invasive margin further harbors cellular immune components including NK cells, macrophages, ILC1s and ILC2s, and a nonimmune cellular component, including fibroblasts. Within the tumor epithelium ILCs, NK cells, B cells, and different T cell subsets are present, including TEX cells,-tumor-specific CD103+CD39+ TRM CTLs and CD103+CD39- bystander TRM cells. Upon ICB, both T and B cell signaling increases. TCF1-expressing TPE cells expand and differentiate into TRM cells migrating to the tumor, where they can exert their cytolytic potential. The ICB response also increases B cell receptor diversity by means of SMH and CSR and induces their clonal expansion and differentiation into advanced antibody-producing plasma cells. TLS: tertiary lymphoid structure, TFH cells: follicular helper T cells, DCs: dendritic cells, GC: germinal center, FDCs: follicular dendritic cells, ILC3: helper-innate lymphoid cell group 3, NK cells: natural killer cells, ILC1: helper-innate lymphoid cell group 1, ILC2: helper-innate lymphoid cell group 2, TEX: terminally exhausted T cells, CTLs: cytotoxic lymphocytes, TRM: tissue resident memory, ICB: immune checkpoint blockade, TCF1: transcription factor 1, TPE: progenitor STEM-like exhausted cells, SMH: somatic hypermutation, RCS: recombinant class switch

    • Sterre T. Paijens
    • Annegé Vledder
    • Hans W. Nijman
    Reviews
    Cellular & Molecular Immunology
    Volume: 18, P: 842-859